Antibody-based surface plasmon resonance sensor platform for monitoring amikacin drug concentrations in human serum samples.

Amikacin (AMK) is a semisynthetic antibiotic used in the treatment of gram-negative bacterial infections and has a narrow therapeutic index. Individualized treatment of amikacin under the guidance of therapeutic drug monitoring (TDM) is important to reduce the occurrence of toxicity and improve clinical efficacy. Current TDM techniques for AMK, such as chromatographic technology and immunoassay, are conducted in central labs using specialized equipment. However, the extensive time and costs involved hinder the application of AMK detection in medical practices. In the present study, a novel surface plasmon resonance (SPR) biosensor for detecting the concentration of AMK in human serum samples was developed and validated. The detection range of SPR method was 0.125 ∼ 8 ng/ml, and the limit of detection was 0.035 ± 0.004 ng/ml. The intra- and inter-day accuracy of SPR was 98 %-105 % and 97 %-110 %, respectively, which met the analytical requirements. The consistency evaluation with the high-performance liquid chromatography (HPLC) method shows that the SPR biosensor is reliable for quantification of AMK. This work is a foundation towards the development of a label-free, real-time, accurate, low cost, and simple method for future TDM, and will help clinicians to optimize dosing regimens thus to maximize the clinical effect and minimize the toxicity of these drugs.